Q-omics provides the consensus-scored LINC02682 profile across patient tissues and cancer cell-line models. LINC02682 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02682 is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, LINC02682 RNA expression shows 8,044 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, BLCA, and TGCT as cancer lineages where LINC02682 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02682 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02682 survival associations across molecular data types. LINC02682 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02682 RNA expression–survival associations across cancer types. High LINC02682 expression shows unfavorable associations in LGG, LAML, BLCA, COAD and SKCM, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .016). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02682 RNA expression.
This table summarizes LINC02682 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02682. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02682 shows lower tumor expression in BLCA, KIRC, UCEC, LUAD and BRCA. The BLCA box plot shows higher LINC02682 RNA expression in normal versus tumor tissue (log2 FC = −0.089, t-test p = .032).
This table shows molecular features associated with LINC02682 in patient tissues and cancer cell lines. In patient samples, LINC02682 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
